ABEO Overview
Upcoming Projects (ABEO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ABEO)
-
A discussion of EB-101 from Abeona Therapeutics as a potential autologous cell therapy in recessive dystrophic epidermolysis bullosa (RDEB)
Tickers: ABEO, KRYS, BBIO
Executed On: Oct 26, 2022 at 08:30 PM EDT
Expired Projects (ABEO)
-
Discussing Abeona’s EB-101 recent Pivotal Phase 3 results in recessive dystrophic epidermolysis bullosa
Ticker: ABEO
Execute By: Dec 31, 2022 -
A discussion on lysosomal storage diseases and where Sangamo (SGMO) and Abeona's genetic treatments fit in.
Tickers: SGMO, ABEO
Execute By: Jul 06, 2017
Upcoming & Overdue Catalysts (ABEO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ABEO)
-
Abeona Therapeutics' (ABEO) gene therapy EB-101 for rare skin-blistering disorder designated by the FDA as orphan drug
Ticker: ABEO
Occurred on: May 25, 2017 -
Further analysis of ABO-102 in treating Sanfilippo syndrome type A (MPS IIIA) due 1Q 2017
Ticker: ABEO
Occurred on: Feb 17, 2017 -
Abeona (ABEO) Enrolls First Patient in Phase 2 Trial Evaluating EB-101 in Epidermolysis Bullosa
Ticker: ABEO
Occurred on: Sep 26, 2016
Strategic Initiatives (ABEO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
